Literature DB >> 7813348

Folate status and adenomatous colonic polyps. A colonoscopically controlled study.

G A Paspatis1, E Kalafatis, L Oros, V Xourgias, P Koutsioumpa, D G Karamanolis.   

Abstract

PURPOSE: The aim of our study was to assess any association of folate with development of colonic adenomas.
METHODS: Serum and red blood cell folate levels were measured in 62 colonoscopically and histologically evaluated patients with colon adenomas (Group A) and in 50 selected colonoscopically negative controls (Group B). Patients with colon polyps underwent colonoscopy for alterations of bowel habits or abdominal pain, and detected polyps were found coincidentally. Controls underwent colonoscopy for alterations of bowel habits or abdominal pain. There was no difference in hematocrit between the two groups.
RESULTS: The mean serum folate level in patients with colonic adenomas was 4.57 ng/ml +/- 2.8 standard deviations (SD), and the mean red blood cells folate levels were 536 ng/ml +/- 273.3 (SD). In controls the mean folate levels in serum and red blood cells were 5.09 ng/ml +/- 2.7 (SD) and 743.8 ng/ml +/- 297.1 (SD), respectively. The red blood cell folate level of colon adenoma patients was statistically lower than the respective level of controls at a highly significant level (P < 0.01).
CONCLUSIONS: We suggest that depressed red blood cell folate levels are associated with development of colonic adenomas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7813348     DOI: 10.1007/bf02053860

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  16 in total

Review 1.  Colon cancer: polyps, prevention, and politics.

Authors:  G L Eastwood
Journal:  Trans Am Clin Climatol Assoc       Date:  1998

2.  Dietary folate protects against the development of macroscopic colonic neoplasia in a dose responsive manner in rats.

Authors:  Y I Kim; R N Salomon; F Graeme-Cook; S W Choi; D E Smith; G E Dallal; J B Mason
Journal:  Gut       Date:  1996-11       Impact factor: 23.059

Review 3.  Chemoprevention of Colorectal Cancer.

Authors:  Bryson W Katona; Jennifer M Weiss
Journal:  Gastroenterology       Date:  2019-09-26       Impact factor: 22.682

4.  An audit of the investigation and treatment of folic acid deficiency.

Authors:  N Haslam; C S Probert
Journal:  J R Soc Med       Date:  1998-02       Impact factor: 5.344

5.  Effect of folic acid supplementation on genomic DNA methylation in patients with colorectal adenoma.

Authors:  M Pufulete; R Al-Ghnaniem; A Khushal; P Appleby; N Harris; S Gout; P W Emery; T A B Sanders
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

6.  Exon-specific DNA hypomethylation of the p53 gene of rat colon induced by dimethylhydrazine. Modulation by dietary folate.

Authors:  Y I Kim; I P Pogribny; R N Salomon; S W Choi; D E Smith; S J James; J B Mason
Journal:  Am J Pathol       Date:  1996-10       Impact factor: 4.307

7.  Serum factors associated with precancerous colonic lesions in acromegaly.

Authors:  M Lombardi; I Scattina; C Sardella; C Urbani; E Marciano; S Signori; L Ruocco; G Pellegrini; E Martino; F Bogazzi
Journal:  J Endocrinol Invest       Date:  2013-01-14       Impact factor: 4.256

8.  Uracil misincorporation into DNA and folic acid supplementation.

Authors:  Aditi Hazra; Jacob Selhub; Wei-Hsun Chao; Per Magne Ueland; David J Hunter; John A Baron
Journal:  Am J Clin Nutr       Date:  2009-11-18       Impact factor: 7.045

9.  Folic acid supplementation inhibits recurrence of colorectal adenomas: a randomized chemoprevention trial.

Authors:  Richard Jaszewski; Sabeena Misra; Martin Tobi; Nadeem Ullah; Jo Ann Naumoff; Omer Kucuk; Edi Levi; Bradley N Axelrod; Bhaumik B Patel; Adhip P N Majumdar
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

10.  Folic acid supplementation for the prevention of recurrence of colorectal adenomas: metaanalysis of interventional trials.

Authors:  Ezzeldin M Ibrahim; Jamal M Zekri
Journal:  Med Oncol       Date:  2009-09-12       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.